This page is an English translation of the Korean original. If there is any discrepancy, the Korean version prevails.
ICD-10: D76.1 | Synonyms: FHL, Familial hemophagocytic lymphohistiocytosis, FHL1~5
Familial hemophagocytic reticulosis (FHL) was first described in 1952 by Farquhar and Claireaux. They first reported pathological findings of histiocytic proliferation, hemophagocytosis and splenomegaly in two siblings who developed the disease in infancy and died rapidly, and named it 'familial hemophagocytic reticulosis.' The name derived from the characteristic pathology at the time in which histiocytes/reticulum cells phagocytose blood cells.
In 1999, Stepp and colleagues identified mutations in PRF1 (perforin 1), the first causative gene of FHL, confirming at the molecular level that FHL is a hereditary immunodeficiency disorder. Subsequently, mutations in UNC13D (FHL3) in 2003, STX11 (FHL4) in 2005 and STXBP2 (FHL5) in 2009 were identified in sequence. These discoveries established that FHL is a genetic defect of the cytotoxic granule secretion pathway (perforin-granzyme pathway).
Until the 1980s, FHL was fatal in almost all cases. After Fischer and colleagues first reported long-term cure of an FHL patient by hematopoietic stem cell transplantation (HSCT) in 1986, HSCT became established as the curative treatment for primary HLH. With the HLH-94 protocol in 1994, standard induction therapy was established.
The core cause of FHL is loss-of-function mutations in genes encoding proteins involved in the perforin-granzyme pathway, by which cytotoxic T lymphocytes (CTLs) and NK cells kill target cells. Normally, in this pathway, activated CTLs/NK cells move lytic granules to the immunological synapse and secrete them to destroy target cells.
| Type | Gene | Chromosomal location | Functional defect |
|---|---|---|---|
| FHL1 | Unknown | 9q21.3-22 | Causative gene unknown |
| FHL2 | PRF1 | 10q22 | Loss of perforin protein function |
| FHL3 | UNC13D(MUNC13-4) | 17q25 | Impaired granule fusion |
| FHL4 | STX11(Syntaxin 11) | 6q24 | Defect in the membrane fusion step |
| FHL5 | STXBP2(MUNC18-2) | 19p13 | Loss of Syntaxin 11 stabilizing function |
In patients with FHL, infection (especially EBV, CMV, influenza) often acts as the trigger for the onset of HLH. Vaccination, trauma, surgery and the like can also rarely be triggers.
All subtypes of FHL (FHL1~5) follow an autosomal recessive mode of inheritance. Carrier parents (each carrying one mutant allele) are clinically normal, but each child has a 25% chance of being affected. The frequency is increased in populations with consanguineous marriage.
The PRF1 p.A91V polymorphism causes a mild reduction in perforin function; it does not cause FHL on its own, but acts as a predisposing factor when combined with other HLH-related variants. UNC13D mutations are reported relatively frequently in East Asian FHL patients, including in Korea, Japan and China. STX11 and STXBP2 mutations are found more often in patients of Turkish, Arab and Kurdish descent.
The penetrance of FHL is very high, and almost all affected individuals develop the disease in childhood. Onset is mostly at age 2 or younger, and with some mild mutations onset may be delayed to adolescence or adulthood.
The incidence of primary HLH, including FHL, is estimated at about 1 per 100,000 newborns (i.e., about 1–2 per million), making it an extremely rare disease. A nationwide study in Sweden reported an incidence of pediatric FHL of about 0.3–1.2 per million children per year.
The male-to-female ratio is nearly equal, and more than 80% develop the disease within the first 12 months of life. The frequency increases in populations with a high rate of parental consanguinity.
The exact incidence of FHL in Korea has not been established, but multicenter studies by the Korean pediatric hematology-oncology society report dozens of cases of primary HLH, including FHL, each year. With improved access to gene panel testing, the rate of identifying genetic causes is increasing.
In a normal cytotoxic immune response, when CTLs and NK cells recognize target cells (virus-infected cells), they secrete cytotoxic granules into the immunological synapse. Perforin forms pores in the target cell membrane, and granzyme B enters the cell and activates caspases to induce cell death (apoptosis). In FHL, the function of key proteins in this pathway is lost, so target cells are not killed.
When target cells are not killed, antigen presentation continues and a cycle of mutual activation of T cells and macrophages is maintained. Inflammatory cytokines such as IFN-γ, TNF-α, IL-6, IL-10, IL-18 are secreted explosively, and macrophages become excessively activated, phagocytosing normal blood cells (hemophagocytosis) and causing a systemic inflammatory response.
Vascular endothelial damage due to the cytokine storm, pancytopenia due to hemophagocytosis and disseminated intravascular coagulation (DIC) due to consumption of coagulation factors combine and progress to multiple organ failure.
Persistent high fever (38.5℃ or higher) appears as an initial symptom and lasts for days to weeks. Lethargy, loss of appetite and weight loss accompany it. Fever without signs of infection that does not respond to antibiotics is the typical initial symptom of FHL.
Pallor, tachycardia and fatigue due to anemia. Petechiae, ecchymoses and mucosal bleeding due to thrombocytopenia. Increased risk of recurrent infections and sepsis due to neutropenia.
Splenomegaly is observed in almost all patients with FHL and causes abdominal distension, abdominal pain and early satiety. Hepatomegaly and abnormal liver function are also commonly present.
Neurological symptoms occur in about 30–50% of patients with FHL, and seizures, altered consciousness, irritability, hypotonia, cranial nerve palsies and others may appear. Nervous system involvement markedly worsens the prognosis.
The main signs are fever of 38.5℃ or higher, splenomegaly with the splenic tip palpable 3 cm or more below the costal margin, jaundice (scleral icterus) and hepatomegaly. Petechiae and ecchymoses of the skin may be observed. With nervous system involvement, neck stiffness, abnormal reflexes and decreased consciousness are present.
Cytopenias affecting two or more lineages on complete blood count. Markedly elevated serum ferritin (often 10,000 ng/mL or higher). Elevated serum triglycerides, decreased serum fibrinogen. Elevated AST/ALT, elevated total bilirubin. Markedly elevated soluble CD25 (sIL-2R). Reduced or absent NK cell cytotoxic activity. Reduced or absent perforin expression on flow cytometry (FHL2).
On bone marrow smear, hemophagocytosis is observed, with activated histiocytes phagocytosing red blood cells, platelets, white blood cells and others.
Active genetic screening is recommended for siblings of patients with FHL. When a mutation in the causative gene is identified, analysis of the same gene in siblings determines early whether they are affected but asymptomatic.
When unexplained persistent fever, splenomegaly and pancytopenia occur together in an infant (age 2 or younger), FHL should be included first in the differential diagnosis. The risk is higher when there is a family history or the child was born to consanguineous parents.
A sharp rise in serum ferritin (>500 ng/mL) is an indication for immediate further testing. NK cell activity testing and confirmation of perforin expression by flow cytometry are useful for screening for FHL.
According to the Histiocyte Society's HLH-2004 criteria, HLH (including FHL) is diagnosed when 5 or more of the 8 diagnostic criteria are met or a molecular genetic diagnosis is confirmed.
FHL is confirmed by identifying mutations in a causative gene (PRF1, UNC13D, STX11, STXBP2). When HLH is clinically suspected and a primary form is possible (age 2 or younger, family history, consanguineous parents, etc.), gene panel NGS testing is performed early in parallel with clinical tests.
In families with confirmed FHL, prenatal diagnosis in subsequent pregnancies is possible by fetal genetic testing through chorionic villus sampling (CVS) or amniocentesis.
The standard induction therapy for FHL is the HLH-94/2004 protocol, an 8-week combination of dexamethasone and etoposide (VP-16). Dexamethasone is given at 10 mg/m²/day for 2 weeks and then tapered, and etoposide is given at 150 mg/m² twice weekly for the first 2 weeks and then once weekly. With central nervous system involvement, intrathecal methotrexate (IT-MTX) and corticosteroids are added.
The curative treatment of FHL is allogeneic hematopoietic stem cell transplantation (allo-HSCT). An HLA-matched sibling donor (MSD) is most ideal, but if none is available, a matched unrelated donor (MUD) or haploidentical transplant is performed. Reduced-intensity conditioning (RIC) transplantation is used as a strategy to lower toxicity while minimizing graft-versus-host disease (GvHD).
Emapalumab, a humanized monoclonal antibody targeting IFN-γ, received FDA approval in 2018 for children with primary HLH that is refractory to or has relapsed after conventional therapy. It is useful as bridging therapy before HSCT.
Without treatment, FHL is a fatal disease leading to death within weeks to months after diagnosis, and in the past the median survival was less than 2 months. Multiple organ failure and bleeding are the direct causes of death.
In the HLH-94 study, the 5-year overall survival (OS) was about 54%. In patients who received HSCT, the 5-year OS was about 60–70%, and HSCT is the key treatment that determines the long-term prognosis.
The prognosis is poor with delayed diagnosis, nervous system involvement, incomplete response to initial induction therapy, infectious complications and PRF1 null mutations.
Early genetic analysis is performed in siblings of patients with confirmed FHL and in siblings born later to determine whether they are affected but asymptomatic. When both parents are carriers, prenatal genetic testing and preimplantation genetic testing (PGT-M) are recommended in subsequent pregnancies.
In patients with FHL and during the period before immune recovery after HSCT, viral infections such as EBV, CMV and HSV are prevented, and intensive treatment is started early when infection occurs. Infection risk is minimized through vaccination (excluding live vaccines).
When fever, pancytopenia and splenomegaly occur together in an infant, HLH differential diagnostic testing is performed immediately, and when FHL is strongly suspected, treatment is started early even before the diagnosis is confirmed, to prevent progression to multiple organ failure.